Intraperitoneal Daptomycin used to Successfully Treat Vancomycin-Resistant Enterococcus Peritonitis

Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. Perit Dial Int 2005; 25: 313–19.

Fried L.F. , Bernardini J. , Johnston J.R. , Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176–82.

Berns J.S. Infection with antimicrobial-resistant micro-organisms in dialysis patients. Semin Dial 2003; 16: 30–7.

Linden P.K. Treatment options for vancomycin-resistant enterococcal infections. Drugs 2002; 62: 425–41.

Bailey E.M. , Faber M.D. , Nafziger D.A. Linezolid for treatment of vancomycin-resistant enterococcal peritonitis. Am J Kidney Dis 2001; 38: 1–3.

Tedla F.M. , Salifu M. , Friedman E.A. Successful treatment of vancomycin-resistant enterococcal peritonitis with linezolid in a kidney transplant patient: a case report and review of the literature. Perit Dial Int 2004; 24: 70–2.

O'Riordan A. , Abraham K.A. , Ho J.K. , Walshe J.J. Vancomycin-resistant peritonitis associated with peritoneal dialysis: a cause for concern. Ir J Med Sci 2002; 171: 42–3.

Lynn W.A. , Clutterbuck E. , Want S. , Markides V. , Lacey S. , Rogers T.R. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin. Lancet 1994; 344: 1025–6.

Moses J. , Brown E. , Lynn W. , White J. , Goldberg L.K. , Talbot G.H. Treatment of vancomycin-resistant Enterococcus faecium CAPD-associated peritonitis with intraperitoneal administration of quinupristin/dalfopristin patients. Presented at the 38th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 24–27, 1998; San Diego, CA, USA.

Rybak M.J. , Hershberger E. , Moldovan T. , Grucz R.G. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062–6.

Poutsiaka D.D. , Skiffington S. , Miller K.B. , Hadley S. , Snydman D.R. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect 2007; 54: 567–71.

Cunha B.A. , Mickail N. , Eisenstein L. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin. Heart Lung 2007; 36: 456–61.

Mortin L.I. , Li T. , Van Praagh A.D. , Zhang S. , Zhang X.X. , Alder J.D. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob Agents Chemother 2007; 51: 1787–94.

Hermsen E.D. , Hovde L.B. , Hotchkiss J.R. , Rotschafer J.C. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother 2003; 47: 3764–7.

Troidle L. , Kliger A.S. , Gorban-Brennan N. , Fikrig M. , Golden M. , Finkelstein F.O. Nine episodes of CPD-associated peritonitis with vancomycin resistant enterococci. Kidney Int 1996; 50: 1368–72.

Lai K.K. Treatment of vancomycin-resistant Enterococcus faecium infections. Arch Intern Med 1996; 156: 2579–84.

Anastasiou D.M. , Thorne G.M. , Luperchio S.A. , Alder J.D. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. Int J Antimicrob Agents 2006; 28: 385–8.

Pankey G. , Ashcraft D. , Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005; 49: 5166–8.

Raad I. , Hanna H. , Jiang Y. , Dvorak T. , Reitzel R. , Chaiban G. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother 2007; 51: 1656–60.

Carpenter C.F. , Chambers H.F. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38: 994–1000.